[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pulmonary-embolism-pe\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pulmonary-embolism-pe":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,44,68,100,135,161,183],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":4},"100645296","pilot-study-evaluating-catheter-directed-thrombolysis-device-in-acute-intermediate-risk-pulmonary-embolism-100645296",false,"NCT07681154","Pilot Study Evaluating Catheter Directed Thrombolysis Device in Acute Intermediate Risk Pulmonary Embolism","Pilot Study to Evaluate the Safety and Feasibility of the Flow Medical Catheter for Catheter-Directed Thrombolysis in Acute Intermediate-Risk Pulmonary Embolism","PE","Inclusion Criteria:\n\nSubjects must meet ALL of the following criteria to be eligible:\n\n1. Age 18 to 75 years, inclusive.\n2. Clinical signs and\u002For symptoms consistent with acute PE with symptom onset ≤14 days prior to baseline CTPA.\n3. CTPA demonstrating acute PE with a filling defect in at least one main or lobar pulmonary artery.\n4. RV\u002FLV diameter ratio ≥0.9 on baseline CTPA (site read acceptable for eligibility determination).\n5. Medically eligible for CDT and standard anticoagulation per institutional guidelines and the treating investigator's judgment.\n6. Willing and able to provide written informed consent and comply with all study procedures and follow-up requirements.\n\nExclusion Criteria:\n\nSubjects meeting ANY of the following criteria are not eligible:\n\n1. High-risk (massive) PE: Sustained SBP \\\u003C90 mmHg for ≥15 consecutive minutes, \\>40 mmHg drop from baseline, vasopressor requirement, or cardiac arrest requiring cardiopulmonary resuscitation during the immediate hospitalization.\n2. Respiratory insufficiency: FiO₂ requirement \\>40% or \\>6 LPM supplemental oxygen to maintain SpO₂ \\>90%.\n3. Prior PE: Prior PE ≤180 days from index procedure.\n4. Absolute contraindications to thrombolytic therapy:\n\n   1. Any prior intracranial hemorrhage (no time limit)\n   2. Known structural cerebrovascular lesion or arteriovenous malformation (no time limit)\n   3. Known malignant intracranial neoplasm (no time limit)\n   4. Ischemic stroke or TIA within 3 months of baseline CTPA\n   5. Intracranial or intraspinal surgery within 2 months of baseline CTPA\n   6. Significant closed-head or facial trauma within 3 months of baseline CTPA\n   7. Suspected aortic dissection\n   8. Active bleeding or bleeding diathesis (excluding menses)\n   9. Active intracranial or intraspinal disease\n   10. Irreversible neurological compromise\n5. Relative contraindications to thrombolytic therapy:\n\n   1. Severe uncontrolled hypertension at presentation (SBP \\>180 mmHg or DBP \\>110 mmHg)\n   2. Major surgery within 3 weeks of baseline CTPA\n   3. Major trauma (non-intracranial) within 3 months of baseline CTPA\n   4. Traumatic or prolonged CPR (\\>10 minutes) within 3 weeks of baseline CTPA\n   5. Recent internal bleeding within 4 weeks of baseline CTPA\n   6. Noncompressible vascular puncture site(s)\n   7. Active peptic ulcer\n   8. Ischemic stroke more than 3 months prior to baseline CTPA\n6. Laboratory exclusions (within 6 hours of index procedure, not correctable prior to procedure):\n\n   1. Platelet count \\\u003C100,000\u002FµL\n   2. Hemoglobin \\\u003C8.0 g\u002FdL\n   3. INR \\>2.0; or INR \\>1.5 if currently receiving warfarin\n   4. aPTT \\>50 seconds in the absence of anticoagulant therapy\n   5. eGFR \\\u003C30 mL\u002Fmin\u002F1.73 m²\n7. Cardiac and pulmonary exclusions:\n\n   1. Known LVEF ≤30% by any imaging modality\n   2. Decompensated heart failure at presentation requiring inotropic or diuretic escalation unrelated to the index PE procedure\n   3. History of chronic lung disease requiring supplemental oxygen therapy at baseline\n   4. Known chronic severe pulmonary hypertension not attributable to the index PE episode (documented PASP \\>70 mmHg by right heart catheterization or echocardiography, or documented CTEPH)\n   5. Profound bradycardia requiring temporary pacing or inotropic support\n8. Procedural and anatomical exclusions:\n\n   1. Known or suspected clot in transit (right atrium or right ventricle), IVC clot, or intracardiac thrombus\n   2. Intracardiac lead in the right ventricle or right atrium placed ≤180 days prior to the index procedure\n   3. Actively progressing cancer actively treated with chemotherapy\n   4. Anatomic or clinical conditions precluding safe venous access or catheter delivery to the pulmonary arteries\n   5. BMI \\>45 kg\u002Fm² if, in the judgment of the investigator, body habitus poses unacceptable risk for vascular access, catheter delivery, or procedural bleeding management\n9. Device and drug hypersensitivity:\n\n   1. Allergy or hypersensitivity to rt-PA (alteplase)\n   2. Heparin allergy or history of heparin-induced thrombocytopenia (HIT)\n   3. Known hypersensitivity to nitinol (nickel-titanium alloy)\n   4. Known anaphylactic reaction to radiographic contrast agents not amenable to premedication\n10. Prior thrombolytic use or glycoprotein IIb\u002FIIIa inhibitor use within 3 days of baseline CTPA.\n11. Use of a direct oral anticoagulant (DOAC) within 48 hours of the index procedure, unless the investigator judges procedural bleeding risk to be acceptable and documents this determination, with rationale, in the subject's medical record.\n12. Pregnancy. A pregnancy test is required for all women of childbearing potential prior to enrollment; point-of-care testing is acceptable. Patients with a positive pregnancy test are excluded. Postpartum patients are eligible if all other criteria are met.\n13. Life expectancy \\\u003C90 days in the investigator's judgment.\n14. Concurrent enrollment in another interventional clinical investigation.\n15. Previous enrollment in this study.\n16. Absolute contraindication to anticoagulation, or inability to receive post-procedure anticoagulation per institutional standard of care.\n17. Unable or unwilling to provide written informed consent.\n18. In the opinion of the investigator, the subject is at unacceptably high risk for bleeding complications or is otherwise not a suitable candidate for the study","ALL","18 Years","75 Years",{"count":21,"type":22},20,"ESTIMATED","INTERVENTIONAL",[25],"NA","This is a pilot study of the Flow Medical Catheter, a catheter-based device used to deliver clot-dissolving medication directly to a blood clot in the lungs (pulmonary embolism). The study evaluates whether the device can be used safely and as intended in adults with intermediate-risk acute pulmonary embolism. All participants receive treatment with the study device; there is no comparison group.",[28,29],"Pulmonary Embolism (PE)","Pulmonary Embolism With Right Ventricle Enlargement",[31],"catheter directed thrombolysis, lysis, lytics, thrombolysis","NOT_YET_RECRUITING","2026-06-26",{"date":35,"type":36},"2026-07-02","ACTUAL",{"date":38,"type":22},"2026-10",{"date":40,"type":22},"2027-06",{"name":42,"class":43},"Flow Medical Solutions, Inc.","INDUSTRY",{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":23,"phases":53,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":64,"locationsCount":67},"100642910","exclusion-of-left-atrial-appendage-thrombus-in-emergency-department-patients-with-atrial-fibrillation-undergoing-ct-to-assess-for-pulmonary-embolus-a-feasibility-study-100642910","NCT07647939","Exclusion of Left Atrial Appendage Thrombus in Emergency Department Patients With Atrial Fibrillation Undergoing CT to Assess for Pulmonary Embolus: A Feasibility Study","ELATE-AF","Inclusion Criteria:\n\n* Patients above 18 years of age years deemed candidates for CT angiography for pulmonary embolism by the primary team on clinical grounds and noted to be in atrial fibrillation at the time.\n* Room air oxygen saturation above 92%\n* Systolic blood pressure above 100 mm Hg\n* Respiratory rate less than 24 breaths\u002Fmin\n\nExclusion Criteria:\n\n* Inability to personally give informed consent\n* Pregnant or breastfeeding individuals\n* Stroke like symptoms\n* ECG criteria for ischemia or infarction\n* Heart rate \\\u003C40 or \\> 120 bpm (inclusive) or 3rd degree heart block\n* Unable to lie flat for at least 10 minutes\n* Unable to follow simple commands\n* Northwell Health Employees.\n* Non-English-speaking patients",{"count":52,"type":22},60,[25],"This study aims to investigate whether a quick, additional CT scan of the heart, performed immediately after a standard CT scan for pulmonary embolism, can effectively detect blood clots in the left atrial appendage (LAA) in patients with atrial fibrillation. Detecting these clots is crucial before certain heart procedures to prevent stroke. Currently, a different, more involved procedure (Transesophageal Echocardiography - TEE) is often used. This study will assess if this additional CT scan is feasible, meaning if it can provide clear enough images to identify LAA clots without needing more contrast dye. The study will involve 60 patients, half receiving an \"ungated\" CT scan and the other half a \"gated\" CT scan (timed with their heart rhythm). The results of these scans will not be used for immediate patient care during the study, but rather to evaluate the CT scan technique itself. There is no direct benefit to participants, but the information gained could lead to faster diagnosis and reduced unnecessary testing for future patients.",[56,28,57],"Atrial Fibrillation (AF)","Left Atrial Appendage Thrombosis","2026-06-09",{"date":60,"type":36},"2026-06-15",{"date":62,"type":22},"2026-07",{"date":40,"type":22},{"name":65,"class":66},"Northwell Health","OTHER",1,{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":72,"acronym":73,"eligibilityCriteria":74,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":75,"targetDuration":4,"studyType":77,"phases":4,"briefSummary":78,"conditions":79,"keywords":85,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":67},"100632914","pulmonary-embolism-and-right-to-left-shunts-100632914","NCT07519876","Pulmonary Embolism and Right-to-Left Shunts","PEaRLS","Inclusion Criteria:\n\n1. Age ≥18\n2. Acute pulmonary embolism (any grade\u002Fsize)\n3. Patient or legally authorized representative is able to provide consent to participate in the study\n\nExclusion Criteria:\n\n1. Patients who, in the opinion of the study investigators, are unable to participate in required study activities\n2. Patients unable to undergo MRI imaging",{"count":76,"type":22},256,"OBSERVATIONAL","Every fetus has a small hole in their heart, called a foramen ovale when they are developing in the womb. For most people this hole closes shortly after birth, but it doesn't close completely in 1 out of every 4 people. This is called a \"patent\" foramen ovale, or PFO. In people with a PFO it is possible for a blood clot in a vein to enter the heart, pass through the opening, and then go into an artery - this is referred to as a paradoxical embolism which passes through a \"Right-to-Left Shunt,\" or RLS. If this occurs, the blood clot can cause a stroke. The most common RLS (more than 90%) is a PFO. Much rarer causes include other types of holes in the heart (like an atrial septal defect, or ASD), or a vascular communication in the lungs (like a pulmonary arteriovenous malformation, or AVM).\n\nWe are investigating whether people with a PE are at higher risk of stroke if they happen to have an RLS compared to PE patients who don't have an RLS. This study will simply observe and compare the differences in stroke-related outcomes between those 2 groups.\n\nParticipation in the study last roughly 90-days and includes the following activities:\n\n* The study team will review your medical records to collect general information such as your age, sex, race\u002Fethnicity, height, weight, medications, medical history, and other medical information\n* Magnetic Resonance Imaging (MRI) of your brain will be done as soon as possible following your enrollment in the study. For more information on MRI scans, please see the \"MRI scan\" section below.\n* A Transcranial Doppler (TCD) with bubble study will be performed to determine if an opening is present in your heart or lungs. TCD is performed using ultrasound. A contrast called agitated saline will be injected into your vein for this test.\n* You will be asked to return for a follow-up visit 90 days after your pulmonary embolism. At this visit, the following will occur:\n\n  1. A second MRI of your brain will be performed.\n  2. You will complete a questionnaire to evaluate whether you may have had a stroke since being discharged from the hospital\n  3. You will meet with a member of the study team who will collect information about your health status.",[28,80,81,82,83,84],"Right-to-Left Shunt","Stroke","Atrial Septal Defects","Patent Foramen Ovale (PFO)","Pulmonary Arteriovenous Malformation",[86,15,80,87,88,81,82,89],"Pulmonary Embolism","PFO","ASD","Patent Foramen Ovale","RECRUITING","2026-04-02",{"date":93,"type":36},"2026-04-09",{"date":95,"type":36},"2026-01-30",{"date":97,"type":22},"2028-01",{"name":99,"class":66},"Tufts Medical Center",{"id":101,"slug":102,"hasResults":11,"nctId":103,"briefTitle":104,"officialTitle":105,"acronym":106,"eligibilityCriteria":107,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":108,"targetDuration":4,"studyType":77,"phases":4,"briefSummary":110,"conditions":111,"keywords":115,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":134},"100630701","repeated-examinations-for-typing-pulmonary-embolism-100630701","NCT07491094","Repeated Examinations for Typing Pulmonary Embolism","Repeated Examinations for Typing Pulmonary Embolism (RE-TyPE)","RE-TyPE","Inclusion Criteria:\n\n1. Adult patients (≥ 18 years old) who is diagnosed with, or followed as out-patients for, PE at Sahlgrenska University Hospital\n2. Written informed consent\n\nExclusion Criteria from Cohort A:\n\n1. Low risk, intermediate-low risk or high risk PE\\*\n2. \\>48 hours since arrival to hospital\n3. Expected inability to comply with the protocol (e.g. dementia)\n\nThere are no exclusion criteria from Cohort B. Patients in Cohort B who are not part of Cohort A may be included at diagnosis (day 0) or at follow-up (\\~day 90).\n\n\\*If biomarkers (and\u002For echocardiography) are not available in hemodynamically stable patients, RV\u002FLV-ratio \\>1 will be considered as preliminary intermediate-high risk. If biomarkers later fall out negative, the patient will be considered as intermediate-low risk and will be moved to Cohort B",{"count":109,"type":22},400,"PURPOSE\n\nThe two related purposes of the RE-TyPE study are:\n\n1. To improve understanding of the early clinical course of intermediate-high risk pulmonary embolism and its association with outcome and\n2. To establish a platform for longitudinal follow-up for all pulmonary embolism at Sahlgrenska University Hospital\n\nHYPOTHESES\n\n1. The dynamic pattern of change, evaluated thorough repeated measures of biomarkers, electrocardiography and echocardiography during the first 48 hours after pulmonary embolism, better predicts outcome than static measurements currently used to predict outcome\n2. Establishment of a platform for longitudinal follow-up will improve quality of care and outcome for patients with pulmonary embolism at Sahlgrenska University Hospital",[112,113,114,29,28],"Pulmonary Embolism (Diagnosis)","Pulmonary Embolism Acute","Pulmonary Embolism With Acute Cor Pulmonale",[116,117,118,119,120,121,122,123,124,125],"Echocardiography","Point Of Care UltraSound (POCUS)","Electrocardiography (ECG)","Biomarkers\u002FBlood","Troponin I","NT-pro-BNP","Lactate","Prediction model","Clinical deterioration","Death",{"date":127,"type":36},"2026-04-06",{"date":129,"type":36},"2026-04-01",{"date":131,"type":22},"2032-01-01",{"name":133,"class":66},"Sahlgrenska University Hospital",3,{"id":136,"slug":137,"hasResults":11,"nctId":138,"briefTitle":139,"officialTitle":140,"acronym":141,"eligibilityCriteria":142,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":143,"targetDuration":4,"studyType":23,"phases":145,"briefSummary":146,"conditions":147,"keywords":148,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":151,"lastUpdatePostDateStruct":152,"startDateStruct":154,"completionDateStruct":156,"leadSponsor":158,"locationsCount":67},"100627773","ultrasound-assisted-catheter-guided-thrombolysis-for-intermediate-high-risk-patients-with-pe-100627773","NCT07452991","ULTRAsound-assisted Catheter-guided Thrombolysis for Intermediate-high Risk Patients With PE","ULTRAsound-assisted Catheter-guided Thrombolysis for Intermediate-high Risk Patients With Pulmonary Embolism","ULTRA-PE","Inclusion Criteria:\n\n* Adults aged ≥ 18 years at time of enrollment;\n* Ability to provide written informed consent (or legally authorized representative consent where applicable);\n* Objectively confirmed acute pulmonary embolism (PE) by contrast-enhanced computed tomography pulmonary angiography (CTPA) demonstrating intraluminal filling defects in at least one segmental, lobar, or more proximal pulmonary artery;\n* Hemodynamically stable at presentation (i.e., not meeting high-risk PE criteria of sustained hypotension, shock, or need for vasopressor support per ESC 2019 and AHA\u002FACC risk stratification);\n* Evidence of right ventricular (RV) dysfunction on imaging (e.g., RV\u002FLV ratio \\> 1.0 on CTPA or echocardiography);\n* Elevated cardiac biomarkers, including troponin I or T above the upper limit of normal;\n* Intermediate-high risk features defined as the combination of imaging RV dysfunction and positive cardiac biomarkers, consistent with ESC stratification;\n* At least one clinical indicator of elevated early risk such as:\n\n  1. Tachycardia (e.g., HR ≥ 100 bpm),\n  2. Mild systolic blood pressure reduction (e.g., SBP ≤ 110 mmHg but not meeting high-risk thresholds),\n  3. Hypoxemia (SpO₂ \\\u003C 90% on room air).\n\nExclusion Criteria:\n\n* Presence of hemodynamic instability, defined as at least one of the following:\n\n  1. Systolic blood pressure (SBP) \\\u003C 90 mmHg or a drop ≥ 40 mmHg from baseline for \\> 15 minutes not attributable to arrhythmia, hypovolemia, or sepsis,\n  2. Requirement for vasopressors to maintain SBP ≥ 90 mmHg,\n  3. Cardiogenic shock, defined by clinical signs of end-organ hypoperfusion (e.g., altered mental status, oliguria, lactate elevation),\n  4. Need for ECMO or other mechanical circulatory support initiated prior to assessment,\n  5. Cardiac arrest requiring resuscitation.\n* Active major bleeding or conditions with high bleeding risk (e.g., known intracranial pathology predisposed to hemorrhage or associated with ongoing pharmacotherapy);\n* Recent (\\\u003C 3 months) intracranial or intraspinal surgery, major trauma, or stroke;\n* Known central nervous system neoplasm or metastatic cancer with high bleed risk.\n* Administration of systemic thrombolytic agents or catheter-directed thrombolysis prior to registry assessment for the index PE episode;\n* Known hypersensitivity to alteplase, unfractionated heparin (UFH), or any of their excipients.\n* Requirement for intensive care admission for conditions unrelated to the index PE;\n* Duration of symptoms attributable to the index PE \\> 14 days at presentation, as defined in contemporary trial criteria;\n* Known severe thrombocytopenia (e.g., platelet count \\\u003C 100 × 10⁹\u002FL) or coagulopathy precluding safe catheter access;\n* Life expectancy \\\u003C 6 months due to advanced comorbid disease unrelated to acute PE;\n* Pregnancy.",{"count":144,"type":22},300,[25],"Pulmonary embolism (PE) is a life-threatening condition and a leading cause of cardiovascular mortality. While systemic thrombolysis is the standard treatment for high-risk PE, its bleeding risk limits use in some patients, highlighting the need for alternative reperfusion strategies such as catheter-directed thrombolysis (CDT). This prospective study will evaluate the safety and efficacy of CDT using the EkoSonic Endovascular System (EKOS; Boston Scientific) in patients with intermediate-high and high-risk PE. The primary outcome is all-cause mortality through 360 days of follow-up, with secondary outcomes including changes in echocardiographic parameters such as the RV\u002FLV diameter ratio.",[28],[149,150],"Pulmonary embolism","Ultrasound-assisted Catheter-guided Thrombolysis","2026-03-13",{"date":153,"type":36},"2026-03-17",{"date":155,"type":36},"2024-09-10",{"date":157,"type":22},"2030-09-10",{"name":159,"class":160},"National Medical Research Center for Cardiology, Ministry of Health of Russian Federation","OTHER_GOV",{"id":162,"slug":163,"hasResults":11,"nctId":164,"briefTitle":165,"officialTitle":166,"acronym":4,"eligibilityCriteria":167,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":168,"enrollmentInfo":169,"targetDuration":4,"studyType":23,"phases":171,"briefSummary":172,"conditions":173,"keywords":4,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":174,"lastUpdatePostDateStruct":175,"startDateStruct":177,"completionDateStruct":179,"leadSponsor":181,"locationsCount":67},"100588847","acostream-use-in-patients-with-high-risk-and-intermediate-risk-acute-pulmonary-embolism-100588847","NCT06946732","Acostream Use in Patients With High Risk and Intermediate-risk Acute Pulmonary Embolism","Acostream Use in Patients With High Risk and Intermediate-risk Acute Pulmonary Embolism (The ARTIST Study)","Inclusion Criteria:\n\n* 18≤Age≤85\n* Clinical symptoms and presentation consistent with pulmonary embolism (PE).\n* PE symptoms duration ≤ 14 days.\n* High risk PE patients with absolute contraindications to systemic thrombolysis or its failure (refractory circulatory collapse) not eligible for surgical embolectomy.\n* Intermediate-high risk PE patients with right ventricle dysfunction (right ventricle\u002F left ventricle \\>0.9) confirmed by computed tomography pulmonary angiography or transthoracic echocardiography.\n\nExclusion Criteria:\n\n* Pregnancy.\n* Refusal to sign the informed consent form.\n* Presence of intracardiac thrombus.\n* Presence of chronic left heart failure with an ejection fraction lower than 30% Diagnosed thrombophilia.\n* History of severe or chronic pulmonary hypertension.\n* Serum creatinine level higher than 1.8 mg\u002Fdl.\n* Known serious and uncontrolled sensitivity to radiographic agents.","85 Years",{"count":170,"type":22},127,[25],"The registry is to evaluate the safety and feasibility of catheter-directed aspiration for patients with high-risk and intermediate-high-risk pulmonary embolism using Acostream.",[28],"2025-04-19",{"date":176,"type":36},"2025-04-27",{"date":178,"type":36},"2025-04-01",{"date":180,"type":22},"2026-12-31",{"name":182,"class":66},"RenJi Hospital",{"id":184,"slug":185,"hasResults":11,"nctId":186,"briefTitle":187,"officialTitle":188,"acronym":189,"eligibilityCriteria":190,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":191,"targetDuration":4,"studyType":77,"phases":4,"briefSummary":193,"conditions":194,"keywords":197,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":203,"lastUpdatePostDateStruct":204,"startDateStruct":206,"completionDateStruct":208,"leadSponsor":210,"locationsCount":67},"100221153","vteval-project---prospective-cohort-studies-to-evaluate-and-improve-diagnostics-management-strategies-and-risk-stratification-in-vte-100221153","NCT02156401","VTEval Project - Prospective Cohort Studies to Evaluate and Improve Diagnostics, Management Strategies and Risk Stratification in VTE","VTEval Project - Three Observational, Prospective Cohort Studies Including Biobanking to Evaluate and Improve Diagnostics, Management Strategies and Risk Stratification in Venous Thromboembolism","VTEval","Inclusion Criteria:\n\n* Age ≥18 years and Informed written consent\n* Clinical condition:\n\n  * Cohort 1: Clinical suspicion of acute PE (with or without DVT)\n  * Cohort 2: Clinical suspicion of acute DVT (without symptomatic PE)\n  * Cohort 3: Incidentally diagnosed VTE",{"count":192,"type":22},2000,"Venous thromboembolism (VTE) with its two clinical manifestations deep vein thrombosis (DVT) and pulmonary embolism (PE) is a life-threatening disease that is associated with considerable morbidity and mortality. The incidence of VTE increases with age and it - as the third most common cardiovascular disease after ischemic heart disease and stroke - represents an important public health problem in industrialized countries with several aspects in need to be addressed.\n\nVTEval Project includes three long-term prospective observational studies to evaluate and improve VTE diagnostics and management, treatment and outcome. The aims of the project include a systematic assessment of VTE, i.e. disease status (symptoms, clinical and subclinical aspects) and risk profiles (classic, psychosocial and environmental factors), using a system-oriented approach. VTEval collects three large prospective cohorts of patients with suspected and incident VTE consisting of individuals with a clinical suspicion of acute PE, individuals with a clinical suspicion of acute DVT, and individuals with incidental diagnosis of VTE).\n\nThe standardized and harmonized data acquisition of the study establishes a sustainable resource for comprehensive research on VTE, thus providing the basis for both short- and long-term analysis.",[195,196,28],"Venous Thromboembolism (VTE)","Deep Vein Thrombosis (DVT)",[198,199,149,200,201,202],"Venous thromboembolism","Deep vein thrombosis","Cohort study\u002Fepidemiology","Outcome","Prognosis","2024-06-14",{"date":205,"type":36},"2024-06-17",{"date":207,"type":36},"2013-04",{"date":209,"type":22},"2030-07",{"name":211,"class":66},"Johannes Gutenberg University Mainz"]